Tyra Biosciences has | Tyra Biosciences has partnered with a patient advocacy group to create an awareness day for upper tract urothelial cancer, a rare tumor type its lead drug candidate targets.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Tyra Biosciences released Phase 2 data for dabogratinib, targeting bladder cancer, aiming to rival J&J's Balversa, with a 60mg…
Explore how AI, advanced analytics and real-world data can help identify rare disease patients earlier, reduce diagnostic delays…
Combination strategies are rapidly redefining treatment for HER2-positive solid tumors. | HER2 combination strategies are…
Early-onset cancers are rising among adults 18–49, reshaping how patients are diagnosed, supported, and engaged. This report…
Due to advances in cancer treatment and early detection, the population of cancer survivors continues to grow, reaching more than
Enhertu’s market conquest is continuing apace. | Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA…
